This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Phototherapy  • Dermatology, Other  • Alert me on articles by topic

Ellen R. M. de Haas, MD, LLM; Henricus J. C. M. Sterenborg, PhD; H. A. Martino Neumann, MD, PhD; Dominic J. Robinson, PhD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The use of topical 5-aminolevulinic acid–photodynamic therapy (ALA-PDT) for the treatment of Bowen disease (squamous cell carcinoma in situ) is gaining acceptance.¹ However, there is limited evidence for the most appropriate treatment regimen, and clinical follow-up remains limited. The treatment of choice for Bowen disease is surgery. Five-year response rates have shown a recurrence rate of 19.0% after conventional surgery and 6.3% after Mohs micrographic surgery.² In a comparison of ALA-PDT and cryotherapy, results significantly favored ALA-PDT.³ In a comparative study of ALA-PDT vs topical fluouracil, recurrence rates at 12 months were 7% and 27%, respectively.⁴

In a review of 11 PDT studies⁵ using broadly similar protocols, response rates of 90% to 100% were found after 1 to 3 treatment sessions, and an average recurrence rate of . . . [Full Text of this Article]

Methods


Results

Comment

AUTHOR INFORMATION